Skip to main content

MOTS-c vs SS-31

Both MOTS-c and SS-31 are used for longevity. Here's how their evidence, dosing, and regulatory status actually compare.

MOTS-c

Evidence B

Mitochondrial-derived peptide MOTS-c

A 16-amino-acid mitochondrial-derived peptide that improves insulin sensitivity and exercise capacity in animal models. Among the most promising 'mitokines' for metabolic aging.

View full MOTS-c profile →

SS-31

Evidence B+

Elamipretide (SS-31)

A cell-permeable tetrapeptide that targets cardiolipin in the inner mitochondrial membrane. Investigated for primary mitochondrial myopathy, heart failure, and dry age-related macular degeneration.

View full SS-31 profile →

Side-by-Side

AttributeMOTS-cSS-31
Evidence GradeBB+
FDA StatusNot FDA-approved — research peptide; multiple early-phase clinical trialsNot FDA-approved — Phase 3 trials for primary mitochondrial myopathy
Typical Dose5–10 mg, 2–3 times weekly (subcutaneous)Trial range: 40 mg subcutaneous daily
Clinics Indexed2229
Categoriesmetabolic, longevitymitochondrial, longevity

Key reported benefits — MOTS-c

  • Insulin sensitivity
  • Exercise capacity
  • Metabolic flexibility

Key reported benefits — SS-31

  • Mitochondrial cardiolipin support
  • ATP production
  • Reduced oxidative damage

Educational use only

This comparison is for educational purposes and not medical advice. Peptide selection should be made with a licensed medical professional based on your individual goals, health history, and current evidence quality.

← Back to all comparisons